Survival on long‐term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting

Crockett, Alan; Cranston, Josephine M; Moss, J. R.; Alpers, J. H.

doi:10.1046/j.1445-5994.2001.00103.x

Cited by 72 publications

(66 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MIYAMOTO et al [16] studied 9,759 patients with COPD, tuberculosis sequelae or chronic interstitial pneumonia receiving long-term oxygen therapy (LTOT) and reported a better survival for females than males. CROCKETT et al [17] studied a population of 505 COPD patients (256 females) also receiving LTOT and confirmed the previous findings. CROCKETT et al [17] also reported that the prognostic factors for females (age, FEV1, BMI and comorbidities) were different from those of males (only BMI).…”

Section: Discussionsupporting

confidence: 73%

“…Four previous studies on highly selected patients with chronic respiratory failure and hypoxaemia have specifically addressed mortality differences between males and females. Three studies [16][17][18] indicated that females with COPD have a better prognosis than males, whereas one concluded the opposite [19]. MIYAMOTO et al [16] studied 9,759 patients with COPD, tuberculosis sequelae or chronic interstitial pneumonia receiving long-term oxygen therapy (LTOT) and reported a better survival for females than males.…”

Section: Discussionmentioning

confidence: 99%

“…The limited available information about sex differences in COPD mortality is derived from studies of patients with advanced stages of disease and hypoxaemic respiratory insufficiency [16][17][18][19].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Sex differences in mortality in patients with COPD

de-Torres

Côté²,

López³

et al. 2008

European Respiratory Journal

117

View full text Add to dashboard Cite

Little is known about survival and clinical prognostic factors in females with chronic obstructive pulmonary disease (COPD). The aim of the present study was to determine the survival difference between males and females with COPD and to compare the value of the different prognostic factors for the disease.In total, 265 females and 272 males with COPD matched at baseline by BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) and American Thoracic Society/European Respiratory Society/Global Initiative of Chronic Obstructive Lung Disease criteria were prospectively followed. Demographics, lung function, St George's Respiratory Questionnaire, BODE index, the components of the BODE index and comorbidity were determined. Survival was documented and sex differences were determined using Kaplan-Meier analysis. The strength of the association of the studied variables with mortality was determined using multivariate and receiver operating curves analysis.All-cause (40 versus 18%) and respiratory mortality (24 versus 10%) were higher in males than females. Multivariate analysis identified the BODE index in females and the BODE index and Charlson comorbidity score in males as the best predictors of mortality. The area under the curve of the BODE index was a better predictor of mortality than the forced expiratory volume in one second for both sexes.At similar chronic obstructive pulmonary disease severity by BODE index and forced expiratory volume in one second, females have significantly better survival than males. For both sexes the BODE index is a better predictor of survival than the forced expiratory volume in one second.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sex differences in mortality in patients with COPD

de-Torres

Côté²,

López³

et al. 2008

European Respiratory Journal

117

View full text Add to dashboard Cite

show abstract

“…A Japanese study of patients treated with LTOT for COPD, tuberculosis sequelae, or interstitial pneumonia showed significantly better survival in women, despite a higher average baseline Pa CO 2 (see Figure E1) (52). This finding was confirmed in a meta-analysis of LTOT in which a survival advantage also existed for women (53). However, Machado and coworkers reported in patients with COPD receiving LTOT that survival was significantly worse in females, those with lower body mass index, and lower Pa O 2 (54).…”

Section: Therapeutic Implicationssupporting

confidence: 69%

Gender and Chronic Obstructive Pulmonary Disease

Han¹,

Postma²,

Mannino³

et al. 2007

Am J Respir Crit Care Med

299

224

View full text Add to dashboard Cite

5Pulmonary and Critical Care Section, Veterans Affairs Health System, Ann Arbor, MichiganThe prevalence of chronic obstructive pulmonary disease (COPD) in women is increasing, as is hospitalization for COPD. The number of women dying of COPD in the United States now surpasses men. Despite this, research suggests that physicians are still more likely to correctly diagnose men with COPD than women. Increased tobacco use in women likely explains some of the increase in the prevalence of COPD in women, but data suggest that women may actually be at greater risk of smoking-induced lung function impairment, more severe dyspnea, and poorer health status for the same level of tobacco exposure. The degree to which these observations represent biologic, physiologic, or sociologic differences is not known. Nonsmokers with COPD are also more likely to be female. In addition, new evidence is emerging that men and women may be phenotypically different in their response to tobacco smoke, with men being more prone to an emphysematous phenotype and women an airway predominant phenotype. Inasmuch as COPD is a disease of inflammation, it is also possible that sexual dimorphism of the human immune response may also be responsible for gender differences in the disease. More data are still needed on what the implications of these findings are on therapy. In this clinical commentary, we present current knowledge regarding how gender influences the epidemiology, diagnosis, and presentation of COPD in addition to physiologic and psychologic impairments and we attempt to offer insight into why these differences might exist and how this may influence therapeutic management.

show abstract

“…However, the difference in mortality between females and males persisted across disease severity. Conversely, we do agree with his comments regarding the more severe patients, especially those with hypoxaemia, as was previously shown by the works of the MIYAMOTO et al [2], CROCKETT et al [3] and FRANKLIN et al [4].…”

Section: From the Authorscontrasting

confidence: 42%